All Stories

  1. Association between peak troponin level and prognosis among patients admitted to intensive cardiovascular care unit
  2. Effect of Glucagon-like Peptide-1 Receptor Agonism on Aortic Valve Stenosis Risk: A Mendelian Randomization Analysis
  3. Correlation between staging classification of aortic stenosis based on the extent of cardiac damage and platelet indices
  4. Exposure to serum from exclusive heated tobacco product smokers induces mTOR activation and fibrotic features in human cardiac stromal cells
  5. Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction
  6. Comprehensive risk management for hypertensive patients
  7. Prediction of 30‐day mortality after surgery for infective endocarditis using risk scores: Insights from a European multicenter comparative validation study
  8. Cardiology 2.0: the (r)age of the machines?
  9. Acute Hyperglycemia-Induced Injury in Myocardial Infarction
  10. Incidence and Predictors of Cerebrovascular Accidents in Patients Who Underwent Transcatheter Mitral Valve Repair With MitraClip
  11. Lifelong impact of adiposity on cardiac structure and function: an alarming signal
  12. Exploring the landscape of academic retractions in medicine: a comprehensive umbrella review
  13. Empagliflozin: primum inter pares among sodium-glucose cotransporter-2 inhibitors?
  14. Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients
  15. Extrasystolic arrhythmia as an atrial fibrillation predictor
  16. A 25-year-long journey into interventional cardiology: looking back, and rushing forward
  17. Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
  18. Transcatheter Mitral Valve Repair With the MitraClip Device for Prior Mitral Valve Repair Failure: Insights From the GIOTTO‐FAILS Study
  19. When Treating Peripheral Artery Disease, Prepare for the Worst, But Hope for the BEST (SFA)
  20. Reevaluating anticoagulation in antiphospholipid syndrome: the role of apixaban in the current treatment paradigm
  21. Statistical primer: individual patient data meta-analysis and meta-analytic approaches in case of non-proportional hazards
  22. ABC as aortic valve, Body Mass Index, COVID, and more: a welcome yet challenging update for cardiovascular practitioners
  23. Which is the best approach for percutaneous coronary intervention of chronic total occlusions? The one you feel most confident with!
  24. N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery?
  25. Lorcaserin: Worthy of Further Insights? Results from Recent Research
  26. Impact of C-reactive protein levels and role of anakinra in patients with ST-elevation myocardial infarction
  27. Kidney Injury After Minimal Radiographic Contrast Administration in Patients With Acute Coronary Syndromes
  28. Impact of heat-not-burn cigarette passive smoking on children's oxidative stress, endothelial and platelet function
  29. ABC as in Arteriopathy, Bleeding, and Coronary disease: Disentangling the prognostic conundrum of patients undergoing percutaneous coronary intervention with concomitant peripheral artery disease
  30. Cardiovascular disease as part of Long COVID: A systematic review
  31. Valvular and vascular calcium: the less the merrier?
  32. European Association of Cardio-Thoracic Surgery (EACTS) expert consensus statement on perioperative myocardial infarction after cardiac surgery
  33. Mechanical cardiopulmonary resuscitation devices: evidence synthesis with an umbrella review
  34. Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score
  35. Catalysts of cardiovascular electromechanical harmony? Unveiling the impact of RAS Inhibitors and ARNI on atrial fibrillation recurrence after ablation
  36. Antiplatelet therapy before transcatheter aortic valve replacement: unravelling the optimal approach
  37. Effect of traditional or heat‐not‐burn cigarette smoking on circulating miRNAs in healthy subjects
  38. Bayesian interpretation of non-inferiority in transcatheter versus surgical aortic valve replacement trials: a systematic review and meta-analysis
  39. Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis
  40. 10 Tips for Planning and Publishing Clinical Research
  41. Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial
  42. Appraising features and outlook of women and men discharged after an acute coronary syndrome: evidence from the 23,700-patient PRAISE International Registry
  43. Does PM 2.5 and PM 10-associated heavy metals affect short-term and long-term survival after out-of-hospital cardiac arrest? Four-year study based on regional registry
  44. Intraprocedural continuous saline infusion lines significantly reduce the incidence of acute kidney injury during endovascular procedures for stroke and myocardial infarction: evidence from a systematic review and meta-regression
  45. Differences in Postoperative Atrial Fibrillation Incidence and Outcomes After Cardiac Surgery According to Assessment Method and Definition: A Systematic Review and Meta‐Analysis
  46. Del Nido cardioplegia for cardiac surgery requiring cardiopulmonary bypass: is the best yet to come?
  47. Low-Dose Paclitaxel-Coated Balloons for Femoropopliteal Disease
  48. Molecular insights on ischemic heart failure: from core genes to hearts
  49. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction
  50. Paclitexel versus sirolimus-coated balloon in the treatment of coronary instent restenosis
  51. Prognostic Impact of Mitral Regurgitation Before and After Transcatheter Aortic Valve Replacement in Patients With Severe Low‐Flow, Low‐Gradient Aortic Stenosis
  52. Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions
  53. Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence
  54. Outcomes of Transcatheter Aortic Valve Replacement in Patients With Severely Reduced Left Ventricular Systolic Function in the Low Systolic Function and Transcatheter Aortic Valve Implantation (LOSTAVI) International Registry
  55. Trimetazidine after coronary revascularization: much ado about nothing?
  56. Lifestyle interventions to change trajectories of obesity-related cardiovascular risk from childhood onset to manifestation in adulthood: a joint scientific statement of the task force for childhood health of the European Association of Preventive Card...
  57. Clinical Impact of OCT-Derived Suboptimal Stent Implantation Parameters and Definitions
  58. Acute coronary syndrome stratification: is it time to go beyond the ECG?
  59. Interleukin‐1 blockade in heart failure: an on‐treatment and off‐treatment cardiorespiratory fitness analysis
  60. Effects of two-month treatment with a mixture of natural activators of autophagy on oxidative stress and arterial stiffness in patients with essential hypertension: A pilot study
  61. Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry
  62. Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
  63. Cardiovascular disease and mental health: a dangerous duo?
  64. Diagnostic Strategies for the Assessment of Suspected Stable Coronary Artery Disease
  65. New approaches to reduce recurrent PCI: to angioplasty and beyond!
  66. Modulation and personalization of therapy after acute coronary syndromes: the road to precision
  67. Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction
  68. Unsupervised Machine Learning with Cluster Analysis in Patients Discharged after an Acute Coronary Syndrome: Insights from a 23,270-Patient Study
  69. Correlation Between Periprocedural Myocardial Infarction, Mortality, and Quality of Life in Coronary Revascularization Trials: A Meta-analysis
  70. Comparison of SYNTAX score strata effects of percutaneous and surgical revascularization trials: A meta-analysis
  71. Is it the time for direct oral anticoagulants in bioprosthetic heart valves?
  72. Statin therapy after myocardial infarction in patients with renal failure: the longer, the merrier!
  73. Vitamin D3 and omega-3 fatty acids: A new approach for cardiovascular prevention
  74. Is female sex impactful in the pathophysiology, presentation, management and outlook of type A acute aortic dissection?
  75. Step-wise Lipid-Lowering Therapy: Thinking Beyond the Guidelines
  76. Dual Pathway Inhibition of Coagulation and Inflammation With Rivaroxaban: A New Therapy Paradigm Against Atherosclerosis
  77. Natural Activators of Autophagy Reduce Oxidative Stress and Muscle Injury Biomarkers in Endurance Athletes: A Pilot Study
  78. ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis
  79. Another meta-analysis on novel oral anticoagulants for left ventricular thrombus: when enough is enough?
  80. Interplay between climate, pollution and COVID-19 on ST-elevation myocardial infarction in a large metropolitan region
  81. Magnitude of Low-density Lipoprotein Reduction and Impact on Major Cardiovascular Outcomes
  82. Should We Consider Recombinant Human Brain Natriuretic Peptide to Prevent Postoperative Atrial Fibrillation?
  83. Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: A network meta-analysis
  84. Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies
  85. Cardiovascular effects of COVID-19 lockdown in professional football players
  86. Cluster analysis of weather and pollution features and its role in predicting acute cardiac or cerebrovascular events
  87. Imatinib as a Tool Against COVID-19: A Balancing Act Between Effectiveness and Cardiac Safety
  88. Surgery in severe valvular heart diseases: when it is too late, too early or right on time?
  89. Anti-Inflammatory Therapy for Acute Coronary Syndromes: Is It Time for a Shift in the Treatment Paradigm?
  90. Unequal opportunities in Italian cardiovascular research: focus on gender
  91. From the Dining Room to the Atrium: Can We Modulate Atrial Fibrillation Risk With Micronutrients?
  92. De-Escalation of Dual Antiplatelet Therapy: Will We Ever Get to the Right Method?
  93. Duration of Dual Antiplatelet Therapy in East Asians: Finding the Balance Between Effectiveness and Safety
  94. Reduction in emergency access for acute myocardial infarction during the COVID-19 pandemic: a survey from the greater area of Rome
  95. Prognostic value of 12-leads admission electrocardiogram in low-risk patients hospitalized for COVID-19
  96. Targeting the NLRP3 inflammasome in cardiovascular diseases
  97. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT-PPM international project
  98. Instantaneous wave‐free ratio‐guided revascularization of nonculprit lesions in STEMI patients with multivessel coronary disease: The WAVE registry
  99. Coronary artery bypass grafting added to surgical aortic valve replacement in octogenarians
  100. The effect of smoking on exhaled carbon monoxide and arterial elasticity during prolonged surgical mask use in the COVID-19 era
  101. Impact of the Gastrointestinal Tract Microbiota on Cardiovascular Health and Pathophysiology
  102. How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators
  103. Commissural Alignment With New-Generation Self-Expanding Transcatheter Heart Valves During Aortic Replacement
  104. Progressive stages of dysmetabolism are associated with impaired biological features of human cardiac stromal cells mediated by the oxidative state and autophagy
  105. Sex-Related Differences in Oxidative, Platelet, and Vascular Function in Chronic Users of Heat-not-Burn vs. Traditional Combustion Cigarettes
  106. Cardiovascular meta-analyses: fool’s gold or gold for fools?
  107. Air pollution and cardiovascular risk: is it time to change guidelines?
  108. Is Smoking Cessation the Best Intervention Ever to Prevent Heart Failure?
  109. The collateral damage of COVID-19 to cardiovascular services: a meta-analysis
  110. Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper.
  111. Transcatheter aortic valve implantation with the novel‐generation Navitor device: Procedural and early outcomes
  112. Challenges of redo cardiac surgery: forewarned is forearmed?
  113. Differential Impact of Type 1 and Type 2 Diabetes Mellitus on Outcomes Among 1.4 Million US Patients Undergoing Percutaneous Coronary Intervention
  114. Estrategia antitrombótica óptima en SCASEST: ¿es la edad sólo un número?
  115. Optimal Antithrombotic Strategy in NSTEACS: Is Age Just a Number?
  116. Severe infrarenal aortic neck angulation alone may not be a predictor of adverse outcomes in the medium term following endovascular aortic aneurysm repair
  117. Impact of weather and pollution on the rate of cerebrovascular events in a large metropolitan area
  118. Cardiovascular medicine: a year in review
  119. Clinical use of cangrelor: a real-world multicenter experience from South Italy
  120. Implantation of one, two or multiple MitraClip™ for transcatheter mitral valve repair: insights from a 1824-patient multicenter study
  121. Age-Related Electrocardiographic Characteristics of Male Junior Soccer Athletes
  122. Computed tomography angiography in blunt cerebrovascular injury: navigating through perspectives and diagnostics
  123. Cerebral protection device out of transcatheter heart procedures: a bridge to surgery
  124. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis
  125. Transcatheter versus surgical aortic valve replacement for severe aortic stenosis: Pat Garrett versus Billy the Kid?
  126. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
  127. Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score
  128. A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache
  129. Characteristics and outcomes of MitraClip in octogenarians: Evidence from 1853 patients in the GIOTTO registry
  130. Pharmacologic treatment of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled clinical trials
  131. Predictors, Treatments, and Outcomes of Do-Not-Resuscitate Status in Acute Myocardial Infarction Patients (from a Nationwide Inpatient Cohort Study)
  132. European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of...
  133. Meta-Analysis of Placebo-Controlled Trials of Levosimendan in Acute Myocardial Infarction
  134. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials
  135. Unraveling diagnostic co-morbidity makeup of each HF category as characteristically derived by ECG- and ECHO-findings, a prevalence analysis
  136. Long-term (≥15 years) Follow-up of Percutaneous Coronary Intervention of Unprotected Left Main (From the GRAVITY Registry)
  137. Renal arteries denervation: from the treatment of resistant hypertension to the treatment of atrial fibrillation
  138. Perirenal Fat: A Novel Risk Factor for CKD Progression in Diabetic Patients
  139. Interpersonal violence: Serious sequelae for heart disease in women
  140. Effects of resistance training on muscle strength, body composition and immune-inflammatory markers in people living with HIV: a systematic review and Meta-analysis of randomized controlled trials
  141. Autoimmune diseases in patients undergoing percutaneous coronary intervention: A risk factor for in-stent restenosis?
  142. Role of Oxidative Stress and Autophagy in Thoracic Aortic Aneurysms
  143. Antithrombotic Therapy for Vascular Disease and Intervention: The Best Is Yet to Come?
  144. Effects of Experimental Interventions to Improve the Biomedical Peer‐Review Process: A Systematic Review and Meta‐Analysis
  145. Use of post-mortem chest computed tomography in Covid-19 pneumonia
  146. Baseline, procedural and outcome features of patients undergoing transcatheter aortic valve implantation according to different body mass index categories
  147. Cardiovascular disease burden: Italian and global perspectives
  148. Instantaneous wave-free ratio-guided revascularization of non-culprit lesion in patients with ST-segment elevation myocardial infarction and multivessel coronary disease: design and rationale of the WAVE Registry
  149. Direct and indirect effects of COVID-19 on acute coronary syndromes: Can we pick the worst?
  150. A novel algorithm for the computation of the diastolic pressure ratio in the invasive assessment of the functional significance of coronary artery disease
  151. Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project
  152. “Effect of permanent right internal mammary artery occlusion on right coronary artery supply: A randomized placebo-controlled clinical trial”
  153. Reply to work from home culture and acute cardiovascular events: A bidirectional conundrum yet to be resolved!
  154. Urinary Dickkopf-3 and Contrast-Associated Kidney Damage
  155. Is COVID-19 the deadliest event of the last century?
  156. Association of admitting physician specialty and care quality and outcomes in non-ST-segment elevation myocardial infarction (NSTEMI): insights from a national registry
  157. The Novel FlexNav Delivery System for Transcatheter Aortic Valve Implantation With the Portico Device: A Case Series
  158. Editorial for “Diagnostic Performance of a Lower‐Dose Contrast Enhanced 4D Dynamic MR Angiography of the Lower Extremities at 3 T Using Multi‐Segmental ...
  159. Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design
  160. Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis
  161. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials
  162. Beneficial effects of a combination of natural product activators of autophagy on endothelial cells and platelets
  163. Expanding the role of fractional flow reserve derived from computed tomography (FFRCT) for the non-invasive imaging of patients with coronary stents: rise of the machines?
  164. Association Between Epicardial Adipose Tissue and Stroke
  165. Impact of chronic use of heat-not-burn cigarettes on oxidative stress, endothelial dysfunction and platelet activation: the SUR-VAPES Chronic Study
  166. Assessing the Best Prognostic Score for Transcatheter Aortic Valve Implantation (from the RISPEVA Registry)
  167. Management of Chronic Stable Angina: Modern Microbiomedical Research Provides Insights Into Traditional Chinese Medicine Treatments
  168. Interplay between COVID-19, pollution, and weather features on changes in the incidence of acute coronary syndromes in early 2020
  169. Ischemia-Reperfusion Injury: Can We Stop the Curing-Hurting Paradox?
  170. Comparing the Safety and Effectiveness of Five Leading New-Generation Devices for Transcatheter Aortic Valve Implantation: Twelve-Month Results From the RISPEVA Study
  171. Angiographic Patency of Coronary Artery Bypass Conduits: A Network Meta‐Analysis of Randomized Trials
  172. Thrombocytopenia Complicating Transcatheter Aortic Valve Implantation: Differences Between Two New-Generation Devices
  173. Perclose Proglide™ for vascular closure
  174. Systematic Reviews and Meta-Analyses in Cardiac Surgery: Rules of the Road – Part 1
  175. Systematic Reviews and Meta-Analyses in Cardiac Surgery: Rules of the Road – Part 2
  176. Minerva Cardiology and Angiology: changing while remaining itself in its journey for cardiovascular evidence
  177. Clinical presentation, therapeutic approach, and outcome of young patients admitted for COVID-19, with respect to the elderly counterpart
  178. Breakthrough healthcare technologies in the COVID-19 era: a unique opportunity for cardiovascular practitioners and patients
  179. Methodologic Considerations on Four Cardiovascular Interventions Trials With Contradictory Results
  180. NLRP3 Inflammasome: A New Promising Therapeutic Target to Treat Heart Failure
  181. Precise Scoring in Patients With Peripheral Artery Disease: The Case for GermanVasc
  182. European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions
  183. Optimal Stent Design for High Bleeding Risk Patients: Evidence From a Network Meta-Analysis
  184. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?
  185. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets
  186. Of Size and Men: A Call for Larger Trials and Meta-Analyses on Vasopressors During General Anesthesia
  187. Renin–Angiotensin Blocking Therapies: A Must—But How?—After Percutaneous Coronary Intervention
  188. T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort
  189. The best way to transcatheter aortic valve implantation: From standard to new approaches
  190. Impact of temporary traffic bans on the risk of acute coronary syndromes in a large metropolitan area
  191. Managing NSTEMI in older patients
  192. Inhibition of miR‐155 Attenuates Detrimental Vascular Effects of Tobacco Cigarette Smoking
  193. A randomized trial comparing the acute coronary, systemic, and environmental effects of electronic vaping cigarettes versus heat-not-burn cigarettes in smokers of combustible cigarettes undergoing invasive coronary assessment: rationale and design of t...
  194. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials
  195. Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery
  196. 339 Interplay between COVID-19, pollution, and weather features on changes in the incidence of acute coronary syndromes in early 2020
  197. 342 Impact of temporary traffic bans on the risk of acute coronary syndromes in a large metropolitan area
  198. Clinical Conundrum: Three Management Strategies for Three-Vessel Coronary Artery Disease?
  199. Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience
  200. Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial
  201. Renal arteries denervation with second generation systems: a remedy for resistant hypertension?
  202. Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis
  203. Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?
  204. Promises and pitfalls of relying on angiography-derived indexes to identify myocardial ischemia: A tale of Romulus and Remus
  205. Accuracy of the "International Criteria" for ECG screening in athletes in comparison with previous published criteria: rationale and design of a diagnostic meta-analysis
  206. Excess all-cause mortality during COVID-19 outbreak: potential role of untreated cardiovascular disease
  207. Veneto's Successful Lesson for a World Shocked by COVID-19: Think Globally and Act Locally
  208. Comparative Indoor Pollution from Glo, Iqos, and Juul, Using Traditional Combustion Cigarettes as Benchmark: Evidence from the Randomized SUR-VAPES AIR Trial
  209. Comparison of Outcomes of Transcatheter Aortic Valve Implantation in Patients ≥85 Years Versus Those <85 Years
  210. Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis
  211. Myocardial perfusion imaging with cadmium–zinc–telluride cameras: Harry Potter and the Radiation Hallows?
  212. Stenting techniques for coronary bifurcation lesions: Evidence from a network meta‐analysis of randomized clinical trials
  213. Association of Radial Artery Graft vs Saphenous Vein Graft With Long-term Cardiovascular Outcomes Among Patients Undergoing Coronary Artery Bypass Grafting
  214. A Stepwise Approach to Systematic Reviews and Meta-analyses of Endovascular Interventions
  215. Characteristics of Contemporary Randomized Clinical Trials and Their Association With the Trial Funding Source in Invasive Cardiovascular Interventions
  216. Risks and benefits of very low levels of low-density lipoprotein cholesterol: When less is not necessarily more
  217. Inflammatory Bowel Disease and Acute Coronary Syndromes: From Pathogenesis to the Fine Line Between Bleeding and Ischemic Risk
  218. Vaping Cardiovascular Health Risks: an Updated Umbrella Review
  219. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients
  220. Management of Structural Heart Disease and Acute Coronary Syndromes in the COVID-19 Pandemic
  221. Focusing on kidneys and platelets in acute coronary syndromes: pre hoc and post hoc risk profiling
  222. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review
  223. Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties
  224. Impact of environmental pollution and weather changes on the incidence of ST-elevation myocardial infarction
  225. Italian cardiovascular expats: global leaders with Italian heartstrings
  226. Effect of exercise on epicardial adipose tissue in adults: a systematic review and meta-analyses
  227. A broken promise
  228. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic
  229. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19)
  230. Degenerative Severe Aortic Stenosis and Concomitant Coronary Artery Disease: What Is Changing in the Era of the “Transcatheter Revolution”?
  231. Do We Really Need Routine CYP2C19 Genotyping?
  232. Fractional Flow Reserve–Based Coronary Artery Bypass Surgery
  233. Myocardial perfusion imaging in patients with unprotected left main disease
  234. Rejuvenating Pheidippides and the Evergreen Benefits of Endurance Training
  235. SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners
  236. Therapeutic Hypothermia in Critically Ill Patients
  237. Impact of Electronic Alternatives to Tobacco Cigarettes on Indoor Air Particular Matter Levels
  238. COVID-19 in Europe: the Italian lesson
  239. Cardiovascular Benefits of Switching From Tobacco to Electronic Cigarettes
  240. Impact of Tirofiban on Serum Troponin Changes in Patients Undergoing Carotid Artery Stenting: A Propensity Matched Analysis
  241. Long-Term Follow-Up of Transcatheter Aortic Valve Implantation With Portico Versus Evolut Devices
  242. Major infections after bypass surgery and stenting for multivessel coronary disease in the randomised SYNTAX trial
  243. Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
  244. Subjective assessment of functional capacity to predict postoperative myocardial injury and death: Hope or hype?
  245. Electronic cigarette
  246. Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction
  247. Clinical outcome after percutaneous coronary intervention with drug-eluting stent in bifurcation and nonbifurcation lesions: a meta-analysis of 23 981 patients
  248. Impact of aspirin on takotsubo syndrome: a propensity score‐based analysis of the InterTAK Registry
  249. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries
  250. Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis
  251. Final results of the ISCHEMIA trial: distinguishing mass media coverage from clinical interpretation
  252. Profiling the Acute Effects of Modified Risk Products: Evidence from the SUR-VAPES (Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking) Cluster Study
  253. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention
  254. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials
  255. Calcific Aortic Valve Stenosis and Atherosclerotic Calcification
  256. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents
  257. Correction to: Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents
  258. New anti-diabetic agents: major advances with unanswered questions
  259. Continuous Positive Airway Pressure and Adaptive Servoventilation in Heart Failure Patients With Central Sleep Apnea With Cheyne Stokes Respiration: Are They Useful in Ameliorating Cardiac Systolic Dysfunction?
  260. Disagreement Between Randomized and Observational Evidence on the Use of Bilateral Internal Thoracic Artery Grafting: A Meta‐Analytic Approach
  261. Comparison of ProGlide vs. Prostar in patients undergoing transcatheter aortic valve implantation
  262. Impact of Predilation Before Transcatheter Aortic Valve Implantation with New-Generation Devices
  263. Non-vitamin K oral anticoagulants for coronary or peripheral artery disease: a systematic review and meta-analysis of mortality and major bleeding
  264. Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index
  265. Comparative one-month safety and effectiveness of five leading new-generation devices for transcatheter aortic valve implantation
  266. Prevalence and Impact of Treatment Crossover in Cardiac Surgery Randomized Trials: A Meta‐Epidemiologic Study
  267. Climate changes and ST-elevation myocardial infarction treated with primary percutaneous coronary angioplasty
  268. Effect of Aerobic Exercise on Peak Oxygen Consumption, VE/VCO2 Slope, and Health-Related Quality of Life in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction: a Systematic Review and Meta-Analysis
  269. On the Road to Regeneration: “Tools” and “Routes” Towards Efficient Cardiac Cell Therapy for Ischemic Cardiomyopathy
  270. Walking or cycling to work to prevent myocardial infarction: Hope or hype?
  271. Commentary: Biochemical Markers for Diagnosis and Follow-up of Aortic Diseases: An Endless Search for the Holy Grail
  272. Paclitaxel in endovascular devices: Identikit of a “serial killer”?
  273. Subocclusive Ostial Left Main Disease After Transcatheter Aortic Implantation with Bail-Out Valve-in-Valve
  274. Three‐Dimensional Echocardiography for Transcatheter Aortic Valve Replacement Sizing: A Systematic Review and Meta‐Analysis
  275. Transcatheter aortic valve implantation for low-flow/low-gradient aortic stenosis
  276. Variability of metabolic parameters and risk of heart failure: Can it be a marker of incident heart failure?
  277. The RADial artery International ALliance (RADIAL) extended follow-up study: rationale and study protocol
  278. Predicting incident peripheral artery disease and critical limb ischemia: Feeling the pulse!
  279. Prediction of long‐term patient outcome after contemporary left main stenting using the SYNTAX and SYNTAX II scores: A comparative analysis from the FAIL‐II multicenter registry (failure in left main study with 2nd generation stents‐Cardiogroup III study)
  280. Cardiovascular Pleiotropic Effects of Natriuretic Peptides
  281. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study
  282. Surgical rescue of guidewire in-stent entrapment during coronary angioplasty
  283. Comparative spallation performance of silicone versus Tygon extracorporeal circulation tubing
  284. Comparative analysis between myocardial perfusion reserve and maximal ischemia score at single photon emission computed tomography with new-generation cadmium-zinc-telluride cameras
  285. Propensity-score-adjusted comparison of Evolut vs. Portico devices for transcatheter aortic valve implantation
  286. Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy?
  287. Comparative Effectiveness and Safety of Polymer-Free Biolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent in All-Comer Patients Undergoing Percutaneous Coronary Interventions
  288. Chemotherapy, cardiovascular disease and precision medicine: Toward truly individualized treatment for precision cardio-oncology?
  289. No guts, no glory for aortic stenosis
  290. Acute Effects of Heat‐Not‐Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome‐Vascular Assessment of Proatherosclerotic Effects of Smoking (SUR‐VAPES) 2 Randomized Trial
  291. Non-invAsive VentIlation for early General wArd respiraTory failurE (NAVIGATE): A multicenter randomized controlled study. Protocol and statistical analysis plan
  292. Bridging aortic valve surgery to 21st century: what can a surgeon do?
  293. Risk of cardiac and sudden death with and without revascularisation of a coronary chronic total occlusion
  294. High-Intensity Interval Training in Patients with Type 2 Diabetes Mellitus: a Systematic Review
  295. Improvement of LDL cholesterol target achievement rates through cardiac rehabilitation after myocardial infarction
  296. Should we climb the next rung in the cerebral protection ladder?
  297. Association between serum magnesium levels and peripheral artery disease: A leg too short?
  298. OUP accepted manuscript
  299. Cupid’s arrow retained in the heart
  300. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
  301. Late Pseudoaneurysm after Manta Use for Transfemoral Aortic Valve Implantation: A Call for Caution?
  302. Plasma CLEC-2 (C-Type Lectin Receptor 2) in Patients With Acute Ischemic Stroke
  303. Hybrid anatomo-functional imaging of coronary artery disease: Beneficial irrespective of its core components
  304. Which came first: The chicken or the egg? Reflecting on the role of polymer and drug in coronary drug-eluting stents
  305. Myocardial-coronary fusion imaging with positron emission tomography and computed tomography: Benchmarking and slingshotting
  306. Dark Chocolate Intake Positively Modulates Redox Status and Markers of Muscular Damage in Elite Football Athletes: A Randomized Controlled Study
  307. Safety of intermediate left main stenosis revascularization deferral based on fractional flow reserve and intravascular ultrasound: A systematic review and meta-regression including 908 deferred left main stenosis from 12 studies
  308. Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet Function
  309. New-generation devices for transcatheter aortic valve implantation
  310. Editorial comment: sandwich carotid stenting: too much of a good thing?
  311. Umbrella review and multivariate meta-analysis of diagnostic test accuracy studies on hybrid non-invasive imaging for coronary artery disease
  312. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
  313. Why Metallic Stents Remain the Worst Type of Endovascular Device, Except for All the Others
  314. Percutaneous coronary intervention or coronary artery bypass graft in left main coronary artery disease
  315. Network meta-analysis of studies comparing closure devices for femoral access after percutaneous coronary intervention
  316. How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure
  317. E-Cigarettes, Incentives, and Drugs for Smoking Cessation
  318. Meta-Analysis comparing Outcomes of Drug Eluting Stents versus Single and Multi-Arterial Coronary Artery Bypass Grafting
  319. Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study
  320. A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure
  321. The Biological Mechanisms of Action of Cardiac Progenitor Cell Therapy
  322. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction
  323. Hybrid invasive coronary imaging with intravascular ultrasound and optical coherence tomography: Informing research and guiding practice
  324. Corrigendum to “Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study” [Int. J. Cardiol. 250 (2018) 80–85]
  325. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study
  326. Impact of specific coronary lesions on regional ischemia at single photon emission computed tomography
  327. Cocaine and acute coronary syndromes: Novel management insights for this clinical conundrum
  328. Intracoronary versus intravenous adenosine to assess fractional flow reserve
  329. High-density lipoprotein-cholesterol functionality and metabolic syndrome
  330. Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery
  331. What is this image? 2018: Image 1 result
  332. Trends in cardiovascular disease in Australia and in the world
  333. Predictors of oxidative stress and vascular function in an experimental study of tobacco versus electronic cigarettes: A post hoc analysis of the SUR-VAPES 1 Study
  334. Missed Opportunities in Cardiac Arrest
  335. Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention
  336. New-generation stents compared with coronary bypass surgery for unprotected left main disease: A word of caution
  337. Vasopressors During Cardiopulmonary Resuscitation. A Network Meta-Analysis of Randomized Trials
  338. Tirofiban Positively Regulates β1 Integrin and Favours Endothelial Cell Growth on Polylactic Acid Biopolymer Vascular Scaffold (BVS)
  339. Commentary: All That Glitters Is Not Zilver: Promises and Disappointments of Endovascular Devices for Superficial Femoral Artery Disease
  340. The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial
  341. Metabolic syndrome and risk of stroke
  342. Statins in adult patients with HIV: Protocol for a systematic review and network meta-analysis.
  343. Epicardial adipose tissue and carotid artery disease
  344. Epicardial adipose tissue and metabolic syndrome
  345. Restenosis, Stent Thrombosis, and Bleeding Complications
  346. Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis
  347. Bridging the Atlantic gap in clinical guidelines for non-ST-elevation acute coronary syndromes
  348. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension
  349. Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study
  350. Hemostasis After Brachial Artery Access With the MynxGrip Device: A Case Report
  351. What We Have Learned from the Recent Meta-analyses on Diagnostic Methods for Atherosclerotic Plaque Regression
  352. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure
  353. Prognostic accuracy of myocardial perfusion imaging in octogenarians
  354. Optical coherence tomography compared with fractional flow reserve guided approach in acute coronary syndromes: A propensity matched analysis
  355. Temporal Trends in the Prevalence, Severity, and Localization of Myocardial Ischemia and Necrosis at Myocardial Perfusion Imaging After Myocardial Infarction
  356. What is the optimal treatment for symptomatic patients with isolated coronary myocardial bridge? A systematic review and pooled analysis
  357. Reply
  358. IVUS and perpheral CTO
  359. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients
  360. Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients
  361. Meta-Analysis of Head-to-Head Comparison of Intracoronary Versus Intravenous Adenosine for the Assessment of Fractional Flow Reserve
  362. MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design
  363. Radial Versus Femoral Access for the Treatment of Left Main Lesion in the Era of Second-Generation Drug-Eluting Stents
  364. Diagnostic Accuracy of Myocardial Perfusion Imaging With CZT Technology
  365. Impact of targeting adenosine-induced transient venous reconnection in patients undergoing pulmonary vein isolation for atrial fibrillation
  366. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis
  367. Impact of coronary revascularization on the clinical and scintigraphic outlook of patients with myocardial ischemia
  368. Interleukin‐1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D‐ HART2 )
  369. Last Nail in the Coffin for Propensity Scores in Observational Cardiovascular Studies?
  370. High sensitive TROponin levels In Patients with Chest pain and kidney disease: A multicenter registry — The TROPIC study
  371. Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease
  372. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting
  373. Cardiac Recovery During Long-Term LVAD
  374. Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents–Cardiogroup III Study)
  375. Erratum to: Prognostic impact of location and extent of vessel-related ischemia at myocardial perfusion scintigraphy in patients with or at risk for coronary artery disease
  376. Commentary: Self-Expanding Stentys System for Significant Infrapopliteal Stenoses: Rainbow Six?
  377. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy
  378. Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?
  379. Cadmium-zinc-telluride myocardial perfusion imaging: The dream of a single test gets nearer
  380. Iteration of second-generation drug-eluting stents: the missing piece of evidence
  381. Rac1 Pharmacological Inhibition Rescues Human Endothelial Dysfunction
  382. Left Atrial Substrate Modification Targeting Low-Voltage Areas for Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta-Analysis
  383. Patterns and trends of transcatheter aortic valve implantation in Italy
  384. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials
  385. What We Learned with Recent Network Meta-analyses on Atherosclerosis Prevention and Treatment
  386. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients
  387. Assessment of the fate of myocardial necrosis by serial myocardial perfusion imaging
  388. Endovascular Therapy for Infrainguinal Artery Disease With Coronary Devices
  389. Normal versus Pathological Cardiac Fibroblast-Derived Extracellular Matrix Differentially Modulates Cardiosphere-Derived Cell Paracrine Properties and Commitment
  390. Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLE-CARDIOGROUP IV and USZ registry
  391. Relationship between Serum Inflammatory Biomarkers and Thrombus Characteristics in Patients with ST Segment Elevation Myocardial Infarction
  392. Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells
  393. Outcomes of patients with low-pressure aortic gradient undergoing transcatheter aortic valve implantation
  394. Comparative safety and effectiveness of coronary computed tomography: Systematic review and meta-analysis including 11 randomized controlled trials and 19,957 patients
  395. Age at Menopause and Extent of Coronary Artery Disease Among Postmenopausal Women with Acute Coronary Syndromes
  396. Accuracy of esophageal pressure to assess transpulmonary pressure during mechanical ventilation
  397. Commentary: Identifying the Best Device for Infrapopliteal Revascularization Through Quantitative Evidence Synthesis
  398. Invasive Management for Elderly Adults with Acute Coronary Syndrome: Where Are We Now?
  399. A EUropean study on effectiveness and sustainability of current Cardiac Rehabilitation programmes in the Elderly: Design of the EU-CaRE randomised controlled trial
  400. Non-HDL-C vs. LDL-C in Predicting the Severity of Coronary Atherosclerosis
  401. Human Lung Spheroids as In Vitro Niches of Lung Progenitor Cells with Distinctive Paracrine and Plasticity Properties
  402. Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function
  403. Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy
  404. Recanalization of a Challenging Chronic Total Occlusion of the Superficial Femoral Artery through the Profunda Femoris Using a Pure Retrograde Technique
  405. Successful Treatment of a Subclavian Artery Stenosis With a Coronary Bioresorbable Vascular Scaffold
  406. A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design
  407. Long-Term (≥10 Years) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents
  408. Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement
  409. Emergency Cardiac Surgery for Irreversible MitraClip Delivery System Entrapment
  410. Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents
  411. Impact of coronary revascularization vs medical therapy on ischemia among stable patients with or suspected coronary artery disease undergoing serial myocardial perfusion scintigraphy
  412. Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients
  413. Coronary surgery is superior to drug eluting stents in multivessel disease. Systematic review and meta-analysis of contemporary randomized controlled trials
  414. Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity matched analysis
  415. Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis
  416. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study
  417. Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis
  418. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis
  419. statins and HIV:
  420. Interleukin-1 Blockade In Acute Decompensated Heart Failure
  421. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond
  422. Commentary: Cilostazol and Carotid Stenting
  423. Umbrella Reviews
  424. Introduction
  425. Conclusion
  426. Designing the Review
  427. Abstracting Evidence
  428. Successful treatment of recurrent carotid in-stent restenosis and drug-eluting balloon failure with a coronary bioresorbable vascular scaffold: A case report
  429. Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era
  430. Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention
  431. Evidence-Based Psychotherapy in Ischemic Heart Disease: Umbrella Review and Updated Meta-Analysis
  432. Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stents – An OCTAVIA Substudy –
  433. Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research
  434. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era
  435. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis
  436. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
  437. Cardiosphere Conditioned Media Influence the Plasticity of Human Mediastinal Adipose Tissue-Derived Mesenchymal Stem Cells
  438. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials
  439. OCT and culprit plaque, metanalysis
  440. Mortality risk with dual antiplatelet therapy? – Authors' reply
  441. Interosseous artery collaterals and their support to ulno-palmar arch: A case report and a review of the literature
  442. Salvaging lowermost deployment of an acurate device during transcatheter aortic valve replacement with balloon and lasso pull techniques
  443. Commentary: Carotid Stent Design
  444. Transcatheter mitral valve repair with mitraclip for significant mitral regurgitation long after heart transplantion
  445. Time to and risk of cardiac events after myocardial perfusion scintigraphy
  446. An International Survey on Taking Up a Career in Cardiovascular Research: Opportunities and Biases toward Would-Be Physician-Scientists
  447. Meta-Analysis of the Usefulness of Mitraclip in Patients With Functional Mitral Regurgitation
  448. Sixty-day readmission rate after percutaneous coronary intervention: predictors and impact on long-term outcomes
  449. Meta-Analysis of Comparison Between Self-Expandable and Balloon-Expandable Valves for Patients Having Transcatheter Aortic Valve Implantation
  450. Long-Term Safety of Drug-Eluting and Bare-Metal Stents
  451. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials
  452. Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: A meta-analysis of 2,581 patients and 2,807 lesions
  453. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis
  454. Heart failure in patients with human immunodeficiency virus
  455. Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention
  456. A multilevel approach to network meta-analysis within a frequentist framework
  457. Eroded Versus Ruptured Plaques at the Culprit Site of STEMI
  458. A Meta-Analysis of Sex-Related Differences in Outcomes After Primary Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction
  459. There’s No Lightning Without a Storm: Complications of Electrophysiology Procedures in Grown-up Congenital Heart Disease
  460. Prognostic impact of location and extent of vessel-related ischemia at myocardial perfusion scintigraphy in patients with or at risk for coronary artery disease
  461. Drug-Coated Balloon Dilation Before Carotid Artery Stenting of Post–Carotid Endarterectomy Restenosis
  462. Commentary: Which Comes First, the Phoenix or the Flame? Reflections on the Role of Inflammation in Patients Undergoing Lower Limb Revascularization for Peripheral Artery Disease
  463. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature
  464. Cardiovascular disease in HIV patients: from bench to bedside and backwards
  465. Network meta-analysis for evidence synthesis: What is it and why is it posed to dominate cardiovascular decision making?
  466. The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS)
  467. Effect of Gender After Transcatheter Aortic Valve Implantation: A Meta-Analysis
  468. Thirty-day readmission rates after PCI in a metropolitan center in Europe
  469. Aspirin underuse, non-compliance or cessation: Definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease
  470. Noncompliance and Cessation of Dual Antiplatelet Therapy After Coronary Stenting
  471. TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN END STAGE RENAL DISEASE: AN ANALYSIS OF THE NATIONWIDE INPATIENT SAMPLE DATABASE
  472. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study Design and Rationale
  473. Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  474. Impact of residual coronary artery disease on patients undergoing TAVI: A meta-analysis of adjusted observational studies
  475. Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)
  476. Miniaturized extracorporeal circulation versus off-pump coronary artery bypass grafting: A meta-analysis of randomized controlled trials
  477. Cardiotoxicity due to chemotherapy for breast cancer: The dark side of the moon
  478. Management of multivessel coronary disease in STEMI patients: A systematic review and meta-analysis
  479. Bridging the Gap between Translational and Outcome Research in Cardiovascular Disease
  480. Pharmacologic and Surgical Interventions to Improve Functional Capacity in Heart Failure
  481. Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients
  482. Bridging regenerative medicine based therapies into the 21st Century: solo or symphony?
  483. Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (from the VCU-Alpha 1-RT Pilot Study)
  484. Heart failure with preserved ejection fraction: Refocusing on diastole
  485. Postpartum valve thrombosis
  486. State of the Art on the Evidence Base in Cardiac Regenerative Therapy: Overview of 41 Systematic Reviews
  487. CARDIOSPHERE CONDITIONED MEDIA INFLUENCE THE PLASTICITY OF HUMAN MEDIASTINAL ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
  488. Cardiotoxicity due to chemotherapy for breast cancer: The dark side of the moon
  489. Usefulness and Validation of the Survival posT TAVI Score for Survival After Transcatheter Aortic Valve Implantation for Aortic Stenosis
  490. The impact of arterial cannulation strategy on operative outcomes in aortic surgery: Evidence from a comprehensive meta-analysis of comparative studies on 4476 patients
  491. ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
  492. Stent selection to minimize the risk of stent thrombosis
  493. Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation
  494. A registry on distal popliteal and infrapopliteal revascularization with coronary drug-eluting stents
  495. A Gender Based Analysis of Predictors of All Cause Death After Transcatheter Aortic Valve Implantation
  496. Commentary: Observations, Trials, and Meta-Analyses: The Life Cycle of Evidence-Based Endovascular Therapy
  497. Impact of Access on TAVI Procedural and Midterm Follow-Up: A Meta-Analysis of 13 Studies and 10,468 Patients
  498. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States
  499. Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban
  500. Mechanisms of Atherothrombosis and Vascular Response to Primary Percutaneous Coronary Intervention in Women Versus Men With Acute Myocardial Infarction
  501. Of genes and men
  502. Impact on Prognosis of Periprocedural Myocardial Infarction after Percutaneous Coronary Intervention
  503. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis
  504. Comparative Risk-Benefit Analysis of Different Classes of Biologic Agents in Patients with Psoriasis: A Case Study on the Pros and Cons of Mixed Treatment Comparison in Synthesizing Complex Evidence Networks
  505. Factors associated with progression of coronary artery disease measured by intravascular ultrasound: Systematic review and meta-analysis
  506. Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  507. The renal artery conundrum: Solving the puzzle of concomitant resistant hypertension and angiographic stenosis
  508. A novel clinically relevant segmentation method and corresponding maximal ischemia score to risk-stratify patients undergoing myocardial perfusion scintigraphy
  509. Percutaneous coronary intervention versus coronary artery bypass graft for stable angina: Meta-regression of randomized trials
  510. A Systematic Review and Collaborative Meta-Analysis to Determine the Incremental Value of Copeptin for Rapid Rule-Out of Acute Myocardial Infarction
  511. Biologic Therapy for Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis: Systematic Review with Pairwise and Network Meta-Analysis
  512. Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials
  513. Commentary: Transcatheter Renal Sympathetic Denervation for Resistant Arterial Hypertension: When Sham Brings Shame?
  514. Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trials
  515. Discontinuation of Dual Antiplatelet Therapy Over 12 Months after Acute Coronary Syndromes Increases Risk for Adverse Events in Patients Treated with Percutaneous Coronary Intervention: Systematic Review and Meta-Analysis
  516. Health-Related Quality of Life After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis: an Updated Review of Literature
  517. Evidence from the Resorbable-polymer stent versus Unresorbable-polymer stent Deployment for coronary Intervention: (RUDI-2) registry
  518. Nephropathy after administration of iso-osmolar and low-osmolar contrast media: Evidence from a network meta-analysis
  519. Optimal aspirin dose in acute coronary syndromes: an emerging consensus
  520. Establishing Comparable Requirements and Treatment Groups Before Applying Statistical Comparison
  521. Establishing Comparable Requirements and Treatment Groups Before Applying Statistical Comparison—Reply
  522. Knowledge and Skill Possible Ability to Represent a Rescue for Personnel Health in the Operating Room
  523. Transcatheter renal sympathetic denervation despite angiographically significant proximal stenosis: Proof of concept from a case report
  524. Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents
  525. Meta-Analysis Comparing Carvedilol Versus Metoprolol for the Prevention of Postoperative Atrial Fibrillation Following Coronary Artery Bypass Grafting
  526. Impact of Diabetes Mellitus on Early and Midterm Outcomes After Transcatheter Aortic Valve Implantation (from a Multicenter Registry)
  527. Network Meta-Analyses: The “White Whale” for Cardiovascular Specialists
  528. Commentary: Choose the Appropriate Access Route in Bovine Arch and You Will Turn a Complex Left Carotid Artery Stenting Procedure Into a Simple One
  529. Our Preoccupation With Renal Artery Disease in Patients Undergoing Cardiac Surgery
  530. Serum and supplement optimization for EU GMP‐compliance in cardiospheres cell culture
  531. Optimizing Intensity and Duration of Oral Antithrombotic Therapy after Primary Percutaneous Coronary Intervention
  532. The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis
  533. A Network Meta-Analysis on Randomized Trials Focusing on the Preventive Effect of Statins on Contrast-Induced Nephropathy
  534. Successful use of the Impella Recover LP 5.0 device for circulatory support during off-pump coronary artery bypass grafting
  535. Left Ventricular Assist Device and Resident Cardiac Stem Cells in Heart Failure: Human Heart’s Potential Matter
  536. Renal Artery Stenosis in Patients Undergoing Major Surgery or otherwise Critically Ill: The Short-Circuit between Association and Causality
  537. New Therapeutic Strategies for Ventricular Remodeling in Acute Myocardial Infarction and Pressure Overload: The Long Way to Heaven
  538. Epicatechin and Catechin Modulate Endothelial Activation Induced by Platelets of Patients with Peripheral Artery Disease
  539. Hematologic indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery or combined procedures: A systematic review with meta-analysis
  540. Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the D-HART Pilot Study)
  541. Long-Term Home Noninvasive Mechanical Ventilation Increases Systemic Inflammatory Response in Chronic Obstructive Pulmonary Disease: A Prospective Observational Study
  542. New Insights into the Steen Solution Properties: Breakthrough in Antioxidant Effects via NOX2 Downregulation
  543. Total Adiponectin Is Inversely Associated with Platelet Activation and CHA2DS2-VASc Score in Anticoagulated Patients with Atrial Fibrillation
  544. Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: The RADIAL PUMP UP Registry
  545. Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
  546. Left Ventricular Assist Devices in Chronic Heart Failure
  547. Quantification of scientific output in cardiovascular medicine: a perspective based on global data
  548. Anaesthetic drugs and survival: a Bayesian network meta-analysis of randomized trials in cardiac surgery
  549. Inaccuracy of available surgical risk scores to predict outcomes after transcatheter aortic valve replacement
  550. Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study
  551. Stent Thrombosis With Drug-Eluting Stents
  552. Percutaneous coronary intervention in nonagenarian
  553. New Oral Anticoagulants and the Risk of Intracranial Hemorrhage
  554. Drugs for attention deficit–hyperactivity disorder do not increase the mid-term risk of sudden death in children: A meta-analysis of observational studies
  555. Can we predict which patients with ST-elevation myocardial infarction benefit most from radial access? Evidence from frequentist and Bayesian meta-regressions of randomized trials
  556. Same wrist intervention via the cubital (ulnar) artery in case of radial puncture failure for percutaneous cardiac catheterization or intervention: The multicenter SWITCH registry
  557. Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial
  558. Choosing the best first line oral drug agent in patients with pulmonary hypertension: Evidence from a network meta-analysis
  559. Temporal Changes in Standard and Tissue Doppler Imaging Echocardiographic Parameters After Anthracycline Chemotherapy in Women With Breast Cancer
  560. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial
  561. Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A meta-analysis of adjusted observational results
  562. No surprising forward jump when deploying a self-expandable stent: Two cases exploiting the combination of Emboshield Nav6 BareWire and Stentys devices
  563. The Virtual histology In CaroTids Observational RegistrY (VICTORY) study: A European prospective registry to assess the feasibility and safety of intravascular ultrasound and virtual histology during carotid interventions
  564. To kiss or not to kiss? Impact of final kissing-balloon inflation on early and long-term results of percutaneous coronary intervention for bifurcation lesions
  565. Drug-coated balloon treatment of coronary artery disease: A position paper of the Italian Society of Interventional Cardiology
  566. Response to letter by Messeri et al
  567. Drug-eluting balloons for peripheral artery disease: A meta-analysis of 7 randomized clinical trials and 643 patients
  568. Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients
  569. Network meta-analyses and mixed treatment comparisons: Are they true scientific endeavors?
  570. Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy
  571. Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: Insights from the FDA reports
  572. Urgent endovascular repair of upper gastrointestinal bleeding from an arterio-biliary fistula with a covered coronary stent
  573. Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis
  574. A Bayesian network meta-analysis for binary outcome: how to do it
  575. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction
  576. 30days and midterm outcomes of patients undergoing percutaneous replacement of aortic valve according to their renal function: A multicenter study
  577. Commentary: Aortoiliac Arteries: AnotherWaterloofor Transcatheter vs. Open Surgical Therapy After Aorta, Cardiac Valves, Carotids, Coronaries, Femorals, and Tibials?
  578. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: The LITE (Liposomal doxorubicin–Investigational chemotherapy–Tissue doppler imaging Evaluation) randomized pilot study
  579. A Critical Review of Meta-Analysis of Adverse Events After Contrast Media
  580. Right versus left radial artery access for coronary procedures: An international collaborative systematic review and meta-analysis including 5 randomized trials and 3210 patients
  581. From big data to bedside decision-making: the case for AdverseEvents
  582. Incidence, etiology and predictors of adverse outcomes in 43,315 patients presenting to the Emergency Department with syncope: An international meta-analysis
  583. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses
  584. Coronary calcification identifies the vulnerable patient rather than the vulnerable Plaque
  585. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
  586. Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: Evidence from a comprehensive network meta-analysis
  587. Endovascular Treatment of Pulmonary Artery Rupture from Pulmonary Artery Catheterization
  588. Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]
  589. Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction
  590. Transcatheter renal sympathetic ablation for resistant hypertension: in vivo insights in humans from optical coherence tomography
  591. Early vessel healing of the Avantgarde cobalt-chromium coronary stent
  592. Meta-analysis of Randomized Trials of Effect of Milrinone on Mortality in Cardiac Surgery: An Update
  593. Commentary: Which Do You Like Better…aBowl of Cheeriosor aBig Mac? Pros and Cons of Meta-Analyses in Endovascular Research
  594. Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse
  595. VASCULAR CLOSURE DEVICES: ARE THEIR USE JUSTIFIED? EVIDENCE FROM A META–ANALYSIS OF RANDOMIZED TRIALS
  596. REVASCULARIZATION OF VIABLE MYOCARDIUM INSIGHTS FROM META-ANALYSES OF RANDOMIZED CLINICAL TRIALS AND RECENT NON-RANDOMIZED STUDIES ON THE EFFECT ON ALL CAUSE MORTALITY USING TRIAL SEQUENTIAL ANALYSES AND META-REGRESSION ANALYSIS
  597. OCT-Based Diagnosis and Management of STEMI Associated With Intact Fibrous Cap
  598. Oral anticoagulants for the secondary prevention of coronary heart disease
  599. Meta-analysis of coronary CT angiography in the emergency department: reply
  600. Optical coherence tomography guided in-stent thrombus removal in patients with acute coronary syndromes
  601. Deferred angioplasty and stenting in primary percutaneous coronary intervention: one step back, two steps forward?
  602. Sex-related differences in carotid plaque features and inflammation
  603. Transradial approach in the catheterization laboratory: Pros/cons and suggestions for successful implementation
  604. Association Between Proximal Stent Edge Positioning on Atherosclerotic Plaques Containing Lipid Pools and Postprocedural Myocardial Infarction (from the CLI-POOL Study)
  605. The Effect of Isoflurane on Survival and Myocardial Infarction: A Meta-analysis of Randomized Controlled Studies
  606. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era
  607. Benefits of   blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
  608. Stent Choice in Patients Undergoing Primary Percutaneous Coronary Intervention
  609. Renal Sympathetic Denervation: From Bench to Bedside or the Other Way Around?
  610. A Novel Closed-Chest Porcine Model of Chronic Ischemic Heart Failure Suitable for Experimental Research in Cardiovascular Disease
  611. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: A meta-regression of randomized clinical trials
  612. Rivaroxaban and risk of myocardial infarction
  613. Intra-aortic Balloon Pump Entrapment in a Transfemoral Sheath:Successful Management with Retrograde Transradial Wiring and Externalization
  614. Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO
  615. Cardiac Remodeling in Obese Patients After Laparoscopic Sleeve Gastrectomy
  616. Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a meta-analysis of randomized clinical trials
  617. Commentary: Drug-Eluting Balloons for Carotid In-Stent Restenosis: Can This Technology Deliver the Goods?
  618. Radial Versus Femoral Randomized Investigation in ST-Segment Elevation Acute Coronary Syndrome
  619. Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial
  620. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study
  621. TCT-15 Histo-Morphometric Evaluation of 2D Characteristics and 3D Sympathetic Renal Nerve Distribution in Hypertensive vs. Normotensive Patients
  622. Pharmacodynamic Effect of Switching Therapy in Patients With High On-Treatment Platelet Reactivity and Genotype Variation With High Clopidogrel Dose Versus Prasugrel: The RESET GENE Trial
  623. Randomized Evidence for Reduction of Perioperative Mortality
  624. Reproducibility of Coronary Optical Coherence Tomography for Lumen and Length Measurements in Humans (The CLI-VAR [Centro per la Lotta contro l'Infarto-VARiability] Study)
  625. Comparison of the Feasibility and Effectiveness of Transradial Coronary Angiography Via Right Versus Left Radial Artery Approaches (from the PREVAIL Study)
  626. Use and Misuse of Multivariable Approaches in Interventional Cardiology Studies on Drug-Eluting Stents: A Systematic Review
  627. Remote ischaemic preconditioning in coronary artery bypass surgery: a meta-analysis
  628. Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
  629. Stent thrombosis with drug-eluting and bare-metal stents – Authors' reply
  630. Risk of Stroke With Coronary Artery Bypass Graft Surgery Compared With Percutaneous Coronary Intervention
  631. Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
  632. Commentary: Use of the 8-F Angio-Seal Vascular Closure Device for Much Larger Sheaths: Successfully Fitting a Square Peg Into a Round Hole?
  633. Stenting vs Medical Therapy for Stable Coronary Artery Disease: A Minefield for Meta-analyses?
  634. Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for the ACEF (age, creatinine, ejection fraction) score
  635. Changing of SYNTAX score performing fractional flow reserve in multivessel coronary artery disease
  636. Synergy Between Direct Coronary Stenting Technique and Use of the Novel Thin Strut Cobalt Chromium Skylor™ Stent: the Mace in Follow Up Patients Treated with Skylor Stent [MILES Study]
  637. A Tailored Approach to Overcoming Challenges of a Bovine Aortic Arch During Left Internal Carotid Artery Stenting
  638. Fenoldopam and Acute Renal Failure in Cardiac Surgery: A Meta-Analysis of Randomized Placebo-Controlled Trials
  639. Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22 740 patients
  640. Does the site of bleeding matter? A stratified analysis on Flocation of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction
  641. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial
  642. Reply to the letter by Dr Erqou regarding “Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients”
  643. TIMI, GRACE and alternative risk scores in Acute Coronary Syndromes: A meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients
  644. Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data
  645. Continuous infusion versus bolus injection of furosemide in pediatric patients after cardiac surgery: a meta-analysis of randomized studies
  646. A comprehensive appraisal of meta-analyses focusing on nonsurgical treatments aimed at decreasing perioperative mortality or major cardiac complications
  647. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
  648. Commentary: Using Vascular Closure Devices Outside the Operating Room: No Reason for Homesickness!
  649. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials
  650. Evidence of a topographical link between unstable carotid plaques and luminal stenosis: Can we better stratify asymptomatic patients with significant plaque burden?
  651. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies*
  652. Milrinone and Mortality in Adult Cardiac Surgery: A Meta-analysis
  653. Remifentanil in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials
  654. Serial Assessment of Coronary Artery Response to Paclitaxel-Eluting Stents Using Optical Coherence Tomography
  655. Beneficial Impact of Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation
  656. Cardiologic side effects of psychotropic drugs
  657. Retrograde popliteal access as bail-out strategy for challenging occlusions of the superficial femoral artery: A multicenter registry
  658. Drug-Eluting Stents in Interventional Cardiology
  659. Potential Pitfalls of Meta-Analyses of Observational Studies in Cardiovascular Research
  660. Repetita iuvant (repeating helps): why another paper on a new stent is important
  661. Reduction of scatter radiation during transradial percutaneous coronary angiography: A randomized trial using a lead-free radiation shield
  662. Examination of the In Vivo Mechanisms of Late Drug-Eluting Stent Thrombosis
  663. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy
  664. Percutaneous tracheostomy, a systematic review
  665. Antegrade Access: Choose the Right Operator and the Right Patient
  666. Reply to letter to the Editor
  667. Adverse Drug Events Due to Potentially Inappropriate Medications—Reply
  668. Novel insights on HIV/AIDS and cardiac disease: shedding light on the HAART of Darkness
  669. High-dose clopidogrel, prasugrel or ticagrelor: trying to unravel a skein into a ball
  670. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis
  671. Percutaneous renal artery intervention versus medical therapy in patients with renal artery stenosis: a meta-analysis
  672. Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot GENOUS trial
  673. Continuous infusion versus bolus injection of furosemide in critically ill patients. A systematic review and meta-analysis.
  674. Nesiritide and clinically relevant outcomes in cardiac surgery: a meta-analysis of randomized studies
  675. Commentary: Devices for Infrainguinal Endovascular Therapy:Menu à la CarteorTable d'Hôte?
  676. Recombinant Activated Factor VII Increases Stroke in Cardiac Surgery: A Meta-analysis
  677. Are propensity scores really superior to standard multivariable analysis?
  678. Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor (Reply to Passaro et al. — Int J Cardiol 2011)
  679. Dual oral antiplatelet therapy and unplanned surgery
  680. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes
  681. Clinically Relevant Outcomes and Long-term Follow-up in Cardiac Anesthesia
  682. Discontinuation of aspirin for secondary prevention
  683. Pushing wrist access to the limit
  684. Percutaneous versus surgical closure of secundum atrial septal defects: a systematic review and meta-analysis of currently available clinical evidence
  685. Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry
  686. Late gadolinium enhancement on cardiac magnetic resonance and phenotypic expression in hypertrophic cardiomyopathy
  687. Response: Does Levosimendan Reduce Mortality in Cardiac Surgery?
  688. Long-term outcomes of elective drug-eluting stenting of the unprotected left main coronary artery in patients with normal left ventricular function
  689. Intracoronary drugs during percutaneous interventions: the highway has different lanes!
  690. Transradial access without preliminary allen test—letter of comment on Rhyne et al.
  691. Comparison of Mortality Rates in Women Versus Men Presenting With ST-Segment Elevation Myocardial Infarction
  692. Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial: A Randomized Comparison of 3 Drug-Eluting Stents in Diabetic Patients
  693. Commentary: The Cardiva Catalyst II Device: A Catalyzer of Patient Safety or a Boomerang for the Endovascular Specialist?
  694. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference
  695. Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction
  696. Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation
  697. Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients
  698. Commentary: What Goes Around Comes Around: The Role of the Subintimal Foot Loop Technique for Limb Salvage
  699. Management of multivessel coronary disease after ST-elevation myocardial infarction treated by primary coronary angioplasty
  700. Limited value of brain natriuretic peptide as a prognostic marker in acute heart failure — A meta-analysis
  701. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences
  702. Mehran Contrast-Induced Nephropathy Risk Score Predicts Short- and Long-Term Clinical Outcomes in Patients With ST-Elevation-Myocardial Infarction
  703. It's never too early! Evidence for rushing your acute coronary patients to the cath lab
  704. Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis
  705. Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: Results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS)
  706. Randomized Clinical Trial on Short-Time Compression with Kaolin-Filled Pad: A New Strategy to Avoid Early Bleeding and Subacute Radial Artery Occlusion after Percutaneous Coronary Intervention
  707. Epidural Analgesia Improves Outcome in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials
  708. Unprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction
  709. Thrombus aspiration in ST elevation myocardial infarction: comparative efficacy in patients treated early and late after onset of symptoms
  710. Percutaneous coronary intervention for small vessel coronary artery disease
  711. Manual versus nonmanual thrombectomy in primary and rescue percutaneous coronary angioplasty
  712. Beneficial impact on cardiovascular risk profile of water buffalo meat consumption
  713. Duplicate meta-analyses on coronary bifurcation strategies: when more is less?
  714. Commentary: Shutting the Door After Antegrade Femoral Arteriotomy: Should You Push, Clip, Tie, or Plug?
  715. Plaque Distribution Patterns in Distal Left Main Coronary Artery to Predict Outcomes After Stent Implantation
  716. Strut Coverage and Vessel Wall Response to Zotarolimus-Eluting and Bare-Metal Stents Implanted in Patients With ST-Segment Elevation Myocardial Infarction
  717. Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)
  718. Miniaturized cardiopulmonary bypass improves short-term outcome in cardiac surgery: A meta-analysis of randomized controlled studies
  719. Optical Coherence Tomography Assessment of In Vivo Vascular Response After Implantation of Overlapping Bare-Metal and Drug-Eluting Stents
  720. The future of new aortic valve replacement approaches
  721. Esmolol Reduces Perioperative Ischemia in Noncardiac Surgery: A Meta-analysis of Randomized Controlled Studies
  722. Thrombus aspiration during primary angioplasty for cardiogenic shock
  723. Swan-Ganz-induced pulmonary artery rupture: Management with stent graft implantation
  724. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel
  725. European Perspectives
  726. Management of restenosis after drug-eluting stent placement for unprotected left main disease
  727. Benefits of coronary revascularization in stable patients in the short and long term after acute myocardial infarction
  728. Reducing Mortality in Cardiac Surgery With Levosimendan: A Meta-analysis of Randomized Controlled Trials
  729. Systematic review and meta‐analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: Much ado about nothing?
  730. Impact of routine angiographic follow-up after percutaneous coronary drug-eluting stenting for unprotected left main disease: the Turin Registry
  731. Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?
  732. Pharmacological Engineering of Endothelial Function and Vessel Response to Drug-Eluting Stents
  733. Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
  734. Results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease according to left ventricular systolic function
  735. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis
  736. Quantitative Coronary Angiography in the Current Era: Principles and Applications
  737. Hemoglobin Levels Predict Exercise Performance, ST-Segment Depression, and Outcome in Patients Referred for Routine Exercise Treadmill Testing
  738. Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure
  739. Spinal Analgesia in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials
  740. A long-term comparison of drug-eluting versus bare metal stents for the percutaneous treatment of coronary bifurcation lesions
  741. Commentary: Below-the-Knee/Ankle Revascularization:Tools of the Trade
  742. Apoptosis in Patients With Acute Myocarditis
  743. Volatile Anesthetics Reduce Mortality in Cardiac Surgery
  744. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
  745. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials
  746. Transradial versus transfemoral approach for percutaneous coronary procedures
  747. Depression and the cardiovascular system: increasing evidence of a link and therapeutic implications
  748. Meta-analytic rage or race for evidence-based interventional cardiology?
  749. Current management of unprotected left main coronary artery disease: Run-in survey of the RITMO (Registro Italiano sul Trattamento del tronco coMune non protettO) study
  750. Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: The sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT)
  751. Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Drug-Eluting Stents
  752. Systematic reviews and meta-analyses “For Dummies”
  753. Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery: A Meta-analysis of Randomized Controlled Studies
  754. Clusterin in Stool: A New Biomarker for Colon Cancer Screening?
  755. Letter by Testa et al Regarding Article, "Presence of Older Thrombus Is an Independent Predictor of Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Thrombus Aspiration During Primary Percutaneous Coronary Intervention"
  756. Infragenicular Stent Implantation for Below-the-Knee Atherosclerotic Disease: Clinical Evidence From an International Collaborative Meta-Analysis on 640 Patients
  757. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points
  758. Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry
  759. Long-term effect of chronic oral anticoagulation: focus on coronary artery disease
  760. Update on Dedicated Bifurcation Stents
  761. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition
  762. Cellular preservation therapy in acute myocardial infarction
  763. Recombinant Activated Factor VII in Cardiac Surgery: A Meta-analysis
  764. Liposomal doxorubicin is less cardiotoxic than epirubicin in patients with breast cancer: evidence from a randomized clinical trial employing biological, tissue Doppler and standard echocardiographic endpoints.
  765. Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease
  766. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction
  767. Very long-term results comparing a simple versus a complex stenting strategy in the treatment of coronary bifurcation lesions
  768. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after myocardial infarction
  769. Desmopressin Reduces Transfusion Needs after Surgery
  770. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis
  771. Impact of diabetes mellitus on early and long-term results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease
  772. Transferring Patients With ST-Segment Elevation Myocardial Infarction for Mechanical Reperfusion: A Meta-Regression Analysis of Randomized Trials
  773. Major improvement of percutaneous cardiovascular procedure outcomes with radial artery catheterisation: results from the PREVAIL study
  774. Anakinra in Experimental Acute Myocardial Infarction—Does Dosage or Duration of Treatment Matter?
  775. Percutaneous coronary implantation of sirolimus-eluting stents in unselected patients and lesions: Clinical results and multiple outcome predictors
  776. Appraising the pathophysiologic impact of coronary collaterals as measured by fractional flow reserve on symptoms and signs of myocardial ischemia
  777. Idiopathic thrombocytopenic purpura and percutaneous coronary stenting: A dangerous duo?
  778. Retrograde percutaneous recanalization of coronary chronic total occlusions: Outcomes from 17 patients
  779. Pexelizumab in ischemic heart disease: A systematic review and meta-analysis on 15,196 patients
  780. The CIAO (Coronary Interventions Antiplatelet-based Only) Study
  781. Overcoming “resistance” to aspirin and clopidogrel with tirofiban: fact or fiction?
  782. Effect of a novel drug-eluted balloon coated with Genistein before stent implantation in porcine coronary arteries
  783. Safety of drug-coated stents
  784. The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease
  785. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial
  786. Right Ventricular Cardiomyocyte Apoptosis in Patients With Acute Myocardial Infarction of the Left Ventricular Wall
  787. EuroSCORE as predictor of in-hospital mortality after percutaneous coronary intervention
  788. Comparison of Assessment of Native Coronary Arteries by Standard Versus Three-Dimensional Coronary Angiography
  789. A prospective multicentre observational study on the management of unprotected left main coronary artery disease: rationale and design of the Registro Italiano sul Trattamento del tronco comune non protetto study
  790. Reply
  791. Sirolimus-eluting stent implantation for bare-metal in-stent restenosis: is there any evidence for a late catch-up phenomenon?
  792. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction
  793. Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry
  794. Percutaneous coronary intervention on left main coronary artery trifurcation
  795. Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease
  796. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
  797. ST-Segment Elevation Myocardial Infarction Due to Early and Late Stent Thrombosis
  798. Comparison of Effectiveness and Safety of Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With Diabetes Mellitus (from the Italian Multicenter Randomized DESSERT Study)
  799. Sudden coronary death, fatal acute myocardial infarction and widespread coronary and myocardial inflammation
  800. Comment on 'Comparison of operator radiation exposure with optimized radiation protection devices during coronary angiograms and ad hoc percutaneous coronary interventions by radial and femoral routes'
  801. Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction
  802. Last nail in the coffin of late lumen loss?
  803. Are Surrogate End Points in Drug-Eluting Stent Trials Reliable?
  804. Late Open Artery Hypothesis in Clinical Practice—Is It a “Dead” Issue?
  805. C-reactive protein and coronary composition in patients with percutaneous revascularization
  806. Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis
  807. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials
  808. Impact of impedance threshold devices on cardiopulmonary resuscitation: A systematic review and meta-analysis of randomized controlled studies
  809. Revisiting the role of percutaneous revascularization versus medical therapy for later infarct-related artery occlusion (letter of comment on Ioannidis and Katritsis. Am Heart J. 2007;154:1065-71)
  810. Clinical and pharmaceutical management of a high-risk diabetic population undergoing percutaneous coronary interventions
  811. Very very late thrombosis of a sirolimus-eluting stent: does suboptimal stent expansion take its toll even after three years?
  812. Survival and Cardiac Remodeling Benefits in Patients Undergoing Late Percutaneous Coronary Intervention of the Infarct-Related Artery
  813. Challenges of Meta-Analyses Pooling Non-Randomized Controlled Studies
  814. Migraine, stroke and patent foramen ovale: a dangerous trio?
  815. Cardiovocal syndrome after transradial cardiac catheterization: An unusual complication
  816. Letter Regarding Article by Solomon et al, "Cardiac Angiography in REnally Impaired Patients (CARE) Study: A Randomized Double-Blind Trial of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease"
  817. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease
  818. Fenoldopam Reduces the Need for Renal Replacement Therapy and In-Hospital Death in Cardiovascular Surgery: A Meta-Analysis
  819. Management of Multivessel Coronary Disease after ST Elevation Myocardial Infarction Treated by Primary Angioplasty
  820. Retrograde septal approach for a challenging chronic total occlusion of the right coronary artery
  821. Repeat thrombolysis or conservative therapy vs. rescue percutaneous coronary intervention for failed thrombolysis: systematic review and meta-analysis
  822. “Trans‐collateral” angioplasty for a challenging chronic total occlusion of the tibial vessels: A novel approach to percutaneous revascularization in critical lower limb ischemia
  823. Aspirin resistance in cardiovascular disease
  824. Potentials and Pitfalls of Meta-analysis on Statins
  825. Adjunctive devices in primary or rescue PCI: A meta-analysis of randomized trials
  826. Early and Long-Term Clinical Results of AngioJet Rheolytic Thrombectomy in Patients With Acute Pulmonary Embolism
  827. Late percutaneous coronary intervention for the totally occluded infarct-related artery: A meta-analysis of the effects on cardiac function and remodeling
  828. European Perspectives
  829. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)
  830. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic
  831. The Retrograde Coronary Approach for Chronic Total Occlusions: Mid-Term Results and Technical Tips & Tricks
  832. Making sense of the recent meta-analytical confusion concerning the safety of drug-eluting stents
  833. Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients
  834. Plantar to dorsalis pedis artery subintimal angioplasty in a patient with critical foot ischemia: a novel technique in the armamentarium of the peripheral interventionist
  835. Protective Effects of Parecoxib, a Cyclo-Oxygenase-2 Inhibitor, in Postinfarction Remodeling in the Rat
  836. Recurrent angina and the problem of inadequate/inappropriate revascularization: reply
  837. Letter by Agostini et al Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern"
  838. Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker’s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aven...
  839. Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction
  840. Letters to the Editor
  841. Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion
  842. Long-Term Clinical and Angiographic Outcomes of Treatment of Unprotected Left Main Coronary Artery Stenosis With Sirolimus-Eluting Stents
  843. Desflurane and Sevoflurane in Cardiac Surgery: A Meta-Analysis of Randomized Clinical Trials
  844. Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION)
  845. Late Restenosis Following Sirolimus-Eluting Stent Implantation
  846. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile
  847. Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes
  848. 368 Assessment of left ventricular systolic dysfunction by tissue Doppler imaging shows evidence of subclinical cardiomyopathy early after anthracycline therapy
  849. Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice
  850. Angioseal use after antegrade femoral arteriotomy in patients undergoing percutaneous revascularization for critical limb ischemia: A case series
  851. Improvement of Cardiac Function With Parecoxib, A Cyclo-oxygenase-2 Inhibitor, in a Rat Model of Ischemic Heart Failure
  852. Ximelagatran Versus Warfarin in the Prevention of Atrial Fibrillation-Related Stroke: Both Sides of the Story
  853. Comment on the 'pilot' GRACIA-2 randomized trial
  854. Recurrent angina after coronary revascularization: a clinical challenge
  855. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients
  856. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression
  857. Apical ballooning syndrome without myocardial necrosis: Proof of concept from a case report
  858. Iatrogenic vessel perforation during below-the-knee percutaneous revascularisation for critical limb ischaemia: successful management with deep catheter intubation and prolonged balloon inflations
  859. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study
  860. Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter
  861. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial
  862. Retrograde pedal artery access for below-the-knee percutaneous revascularisation
  863. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent
  864. Angiographic Analysis of Pattern of Late Luminal Loss in Sirolimus- and Paclitaxel-Eluting Stents
  865. Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews
  866. Clinical Implications of the PROTECT–TIMI-30 Trial
  867. Outcome of Overlapping Heterogenous Drug-Eluting Stents and of Overlapping Drug-Eluting and Bare Metal Stents
  868. Left Ventricular Diastolic Filling Pattern at Doppler Echocardiography and Apoptotic Rate in Fatal Acute Myocardial Infarction
  869. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients
  870. Essential thrombocythemia presenting as unstable angina pectoris: What should the cardiologist know?
  871. An unusual cause of fatal pulmonary embolism
  872. Plaque vulnerability and related coronary event prediction by intravascular ultrasound with virtual histology: “It's a long way to tipperary”?
  873. Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: A multicenter prospective registry of 150 consecutive patients
  874. Meta-Analysis of the Studies Assessing Temporal Changes in Coronary Plaque Volume Using Intravascular Ultrasound
  875. Antegrade access in a stented common femoral artery: Feasible but with a real bleeding risk
  876. Beneficial Impact of Fenoldopam in Critically Ill Patients With or at Risk for Acute Renal Failure: A Meta-Analysis of Randomized Clinical Trials
  877. Rationale for intracoronary administration of abciximab
  878. Mastering the antegrade femoral artery access in patients with symptomatic lower limb ischemia: Learning curve, complications, and technical tips and tricks
  879. Diagnostic Performance of Multislice Spiral Computed Tomography of Coronary Arteries as Compared With Conventional Invasive Coronary Angiography
  880. The Hurdles of Warfarin and the Hurdles of Clinical Practice
  881. Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
  882. Coroscanner versus coronarographie : resultats d’une meta-analyse a partir de 1349 patients et 17 585 segments
  883. Elective versus provisional intraaortic balloon pumping in unprotected left main stenting
  884. From Chaotic to Coordinated Clinical Research: The Case of Acetylcysteine
  885. C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator
  886. Low-Dose Aspirin for Stroke Prevention
  887. Drug-Eluting Stent Restenosis
  888. Inaccuracy of dipyridamole echocardiography or scintigraphy for the diagnosis of coronary artery disease in patients with both left bundle branch block and left ventricular dysfunction
  889. A pilot study with a new, rapid‐exchange, thrombus‐aspirating device in patients with thrombus‐containing lesions: The Diver C.E. study
  890. Potentials and pitfalls of clinical outcome research studies in cardiac surgery
  891. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease
  892. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: Insights from the TRUE (Taxus™ in Real-life Usage Evaluation) Study
  893. Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary In-Stent Restenosis
  894. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction
  895. Is Late Luminal Loss an Accurate Predictor of the Clinical Effectiveness of Drug-Eluting Stents in the Coronary Arteries?
  896. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: Insights from a systematic overview of randomized trials in light of the drug-eluting stent era
  897. Impaired coronary and myocardial flow in severe aortic stenosis is associated with increased apoptosis: a transthoracic Doppler and myocardial contrast echocardiography study
  898. Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina
  899. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study
  900. The drug-eluting stent dilemma: comparing the effectiveness of Cypher versus Taxus
  901. Drawbacks of Nonrandomized Trials in Acute Coronary Syndromes
  902. 90 The effects of right ventricular pacing on ventricular synchrony studied by tissue Doppler echocardiography: A prospective study in patients undergoing single/dual chamber pacemaker implantation
  903. Percutaneous safenectomy: A potentially dreadful complication of cutting balloon angioplasty in safenous vein grafts
  904. New insights into molecular mechanisms of diffuse coronary ectasiae: A possible role for VEGF
  905. A novel approach to chronic total occlusions: The crosser system
  906. Ischemic cardiomyopathy, left coronary trunk hypoplasia and subsidiary coronary supply from the descending thoracic aorta
  907. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI
  908. Clinical Outcome Following Aleatory Implantation of Paclitaxel-Eluting or Sirolimus-Eluting Stents in Complex Coronary Lesions
  909. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation†
  910. Left ventricular hypertrophy, apoptosis, and progression to heart failure in severe aortic stenosis
  911. C-Reactive Protein is Associated with Malignant Ventricular Arrhythmias in Ischemic Patients with Implantable Cardioverter Defibrillator
  912. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients
  913. Coronary vasospasm secondary to hypercholinergic crisis: An iatrogenic cause of acute myocardial infarction in myasthenia gravis
  914. 17-Beta-Estradiol Eluting Stent Versus Phosphorylcholine-Coated Stent for the Treatment of Native Coronary Artery Disease
  915. Long-term Benefits of an Early Invasive Management in Acute Coronary Syndromes Depend on Intracoronary Stenting and Aggressive Antiplatelet Treatment: A Meta-regression
  916. Oral anticoagulants for the secondary prevention of coronary heart disease
  917. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium
  918. Manual Thrombus-Aspiration Improves Myocardial Reperfusion
  919. Use of a novel high-osmolar gadolinium chelate, gadobutrol, for percutaneous renal artery stenting in two patients with chronic renal failure
  920. Complete myocardial revascularization: between myth and reality
  921. Complete myocardial revascularization: between myth and reality: reply
  922. ST-segment elevation acute myocardial infarction: reperfusion at any cost?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
  923. Critical role of bare-metal stent controls in trials of drug-eluting stents
  924. Validation of Predictors of Intraprocedural Stent Thrombosis in the Drug-Eluting Stent Era
  925. Coronary stenting in small vessels
  926. The difficult task of glycaemic control in diabetics with acute coronary syndromes: finding the way to normoglycaemia avoiding both hyper- and hypoglycaemiaThe opinions expressed in this article are not necessarily those of the Editors of the European ...
  927. Fatal choking due to amyloid infiltration of the laryngeal plexus
  928. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis
  929. Catheter-induced straightening of external iliac tortuosity: a cause of pseudostenosis to be borne in mind
  930. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials
  931. Rescue percutaneous coronary intervention for failed thrombolysis in a patient with anomalous coronary arteries
  932. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression
  933. Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction
  934. CORRECTION
  935. Hibernating myocardium, apoptosis, and a simple mathematical task
  936. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials
  937. Coronary stenting versus balloon angioplasty in small vessels
  938. Reduced post-infarction myocardial apoptosis in women: a clue to their different clinical course?
  939. Suicide by Pencil
  940. Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction
  941. PCNA expression in ischemic cardiomyopathy: DNA repair, myocyte regeneration or just another type of myocyte death?
  942. Commentary
  943. Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A European Perspective
  944. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials
  945. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures
  946. Widespread Myocardial Inflammation and Infarct-Related Artery Patency
  947. Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
  948. Commentary
  949. Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease
  950. Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence
  951. Clinical manifestations of coronary aneurysms in the adult as possible sequelae of Kawasaki disease during infancy
  952. Is vasopressin superior to adrenaline or placebo in the management of cardiac arrest? A meta-analysis
  953. Cyclooxygenase-2 in myocardial ischemia
  954. Soluble interleukin-2 receptor: is there a role in ischaemic cardiomyopathy?
  955. Right ventricular dilatation after left ventricular acute myocardial infarction is predictive of extremely high peri-infarctual apoptosis at postmortem examination in humans
  956. High-risk clinical features predict increased post-infarction myocardial apoptosis and the benefits as a result of an open infarct-related artery
  957. Potential Antiapoptotic Activity of Aldosterone Antagonists in Postinfarction Remodeling
  958. 216 Reduced apoptosis and bax expression after myocardial infarction in females are potential explanations of sex-specific differences in cardiac remodelling
  959. 406 Right ventricular dilatation following left ventricular acute myocardial infarction is predictive of extremely high peri-infarctual apoptosis at post-mortem examination in humans
  960. 534 The Norris coronary prognostic index predicts increased post-infarction myocardial apoptosis at post-mortem examination in humans
  961. 681 Cyclooxygenase-2 (COX-2) expression at site of recent myocardial infarction: friend or foe
  962. Atherothrombosis, inflammation, and diabetes
  963. P1722 Left-ventricular jeopardized myocardium remote from necrotic areas is extensively affected from apoptotic myocardiocyte loss after acute myocardial infarction
  964. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure
  965. The ‘Open-Artery Hypothesis’: New Clinical and Pathophysiologic Insights
  966. C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary Syndromes
  967. Re: Kodaet al. Myocytes positive forin situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure.J Pathol 2003; 199: 229-236
  968. Myocardiocyte loss due to apoptosis
  969. Early revascularisation for myocardial infarction
  970. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling
  971. Persistent Infarct-Related Artery Occlusion Is Associated With an Increased Myocardial Apoptosis at Postmortem Examination in Humans Late After an Acute Myocardial Infarction
  972. Antioxidant Vitamins and Coronary Disease
  973. B-Type Natriuretic Peptide and Acute Coronary Syndromes
  974. Blood Pressure and Death from Coronary Heart Disease
  975. Therapeutic efficiency of tirofiban in acute coronary syndromes
  976. A Critical Review of Meta-Analysis of Adverse Events After Contrast Agents